Combined Use of Bacteroides Fragilis and BCAAs on HBsAg Clearance

The goal of this prospective observational study is to determine the effects of concomitant administration of Bacteroides fragilis and Branched-Chain Amino Acids on hepatitis B virus clearance. The primary question it aims to answer is whether this concomitant administration can promote HBV clearance. The study will observe the HBV clearance rate in chronic hepatitis B patients who receive Bacteroides fragilis and BCAA as a supplement to their routine antiviral therapy. For comparison, researchers will compare the clearance rate in this group to that observed in a control group of chronic hepatitis B patients receiving a standard antiviral regimen based on PegIFNα2b and nucleoside analogs.

NCT Number	NCT07257562
Lead Sponsor	First Affiliated Hospital of Fujian Medical University
Conditions	Chronic Hepatitis B
Enrollment	40 participants
Start Date	2025-06-01
Primary Completion	2026-03-01 (estimated)
Study Completion	2026-12-01 (estimated)
Updated on ClinicalTrials.gov	2025-12-02